MedCity News January 16, 2025
Galapagos and Gilead Sciences have both evolved since inking their R&D collaboration agreement in 2019. Separating Galapagos into two offers a way for that company to pursue its cell therapy strategy while also keeping the Gilead alliance alive, executives from both companies said.
When Galapagos and Gilead Sciences entered a global drug R&D collaboration six years ago, the deal focused on Galapagos’s capabilities as a developer of small molecule drugs. Fast forward to today, and the strategies and ambitions of both companies are less complementary.
Galapagos, no longer interested in developing small molecules, is focusing on cell therapy, an area where Gilead already has a strong presence. Since the 2019 deal, both companies and the biotech industry have evolved, Galapagos...
Today's Sponsors
Today's Sponsor